EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications

Le Yu, Ian J Davis, Pengda Liu iD

Cancers · 06.01.2023 · 15 (2) · 382

DOI: 10.3390/cancers15020382 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.01.2023. Verfasst von Le Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, UNC University Cancer Research Fund, Andrew McDonough B+ Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ewing sarcoma is the second most common bone tumor in childhood and adolescence. Currently, first-line therapy includes multidrug chemotherapy with surgery and/or radiation. Although most patients initially respond to chemotherapy, recurrent tumors become treatment refractory. Pathologically, Ewing sarcoma consists of small round basophilic cells with prominent nuclei marked by expression of surface protein CD99. Genetically, Ewing sarcoma is driven by a fusion oncoprotein that results from one of a small number of chromosomal translocations composed of a FET gene and a gene encoding an ETS family transcription factor, with ~85% of tumors expressing the EWSR1::FLI1 fusion. EWSR1::FLI1 regulates transcription, splicing, genome instability and other cellular functions. Although a tumor-specific target, EWSR1::FLI1-targeted therapy has yet to be developed, largely due to insufficient understanding of EWSR1::FLI1 upstream and downstream signaling, and the challenges in targeting transcription factors with small molecules. In this review, we summarize the contemporary molecular understanding of Ewing sarcoma, and the post-transcriptional and post-translational regulatory mechanisms that control EWSR1::FLI1 function.

Schlagwörter

Stichwörter der Autor:innen

EWSR1-FLI1Ewing sarcomapost-translational modificationstargeted therapytranscriptional regulation

Autor:innen und Institutionen

  • Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Pengda Liu

Förderung

  • NCI NIH HHS
  • UNC University Cancer Research Fund
  • Andrew McDonough B+ Foundation
  • Andrew McDonough B+ Foundation Award
  • NIH

Zitieren

APA

Yu, L., Davis, I. J., & Liu, P. (2023). Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications. Cancers, 15(2), 382. https://doi.org/10.3390/cancers15020382

Vancouver

Yu L, Davis IJ, Liu P. Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications. Cancers. 2023;15(2):382. doi:10.3390/cancers15020382

BibTeX
@article{Yu2023,
  author = {Yu, Le and Davis, Ian J and Liu, Pengda},
  title = {Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {382},
  doi = {10.3390/cancers15020382}
}
Kostenlos starten →